Global Cysticercosis Treatment Market, By Drug Class (Antiparasitic therapy, Corticosteroids, Antiepileptic drugs, Surgery), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Cysticercosis Treatment Market Analysis and Size
The global cysticercosis treatment market is expected to witness significant growth during the forecast period. The maximum frequency of infections is mainly caused by the Taenia solium variety of tapeworms that are mostly found in pork. The rise in the adoption of cysticercosis treatment and evolving economies such as China, India and others will create new opportunities for the global cysticercosis treatment market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global cysticercosis treatment market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Cysticercosis is also known as pork tapeworm infection, defined as protozoan infections mainly caused by larval cysts of the tapeworm taenia solium affecting the brain, muscle and other tissues. It is primarily spread by closed contact with dirty hands of contaminated food, fluid, and sudden headaches and lumps under the skin. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Cysticercosis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Antiparasitic therapy, Corticosteroids, Antiepileptic drugs, Surgery), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K), Bayer AG (Germany), Strides Pharma Science Limited (India)
|
|
Market Opportunities
|
|
Global Cysticercosis Treatment Market Dynamics
Drivers
- Rising Incidence of Parasitic Infection
According to the International Journal of Surgery records, Neurocysticercosis (NCC) is the most common parasitic infestation of the brain, and it is projected that almost 50 million people worldwide suffer from this disease. About, 50,000 individuals with Neurocysticercosis die each year because of the disease. Thus, this boosts the market growth.
Opportunities
- Rise in adoption of cysticercosis treatment
Increase in adoption of cysticercosis treatment in developing economies such as China and India is anticipated to offer substantial opportunities for the global cysticercosis treatment market.
- Increase in Protozoan Infections
Increase in the cases of protozoan infections globally and a lack of sanitation practices in some of the developing countries are projected to boost the cysticercosis treatment market during the forecast period. Thus, it creates an opportunity for the market growth.
Restraints/Challenges
- Complications of cysticercosis
The disease's major complications mainly include brain edema, chronic meningitis, vasculitis, paralysis, hydrocephalus, coma, partial blindness, seizures, and death. This acts as a major hindrance in the market growth.
• Higher cost of research & development
Higher cost of research & development and increasing frequency of severe reactions, due to the body’s inflammatory reaction to the dying parasites, are major factors limiting the global cysticercosis treatment market.
This global cysticercosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cysticercosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cysticercosis Treatment Market Scope
The global cysticercosis treatment market is segmented on the basis of drug, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Antiparasitic therapy
- Albendazole
- Corticosteroids
- Dexamethasone
- Prednisone
- Antiepileptic drugs
- Praziquantel
- Albendazole
- Surgery
Drug Type
- Branded
- Generic
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cysticercosis Treatment Market Regional Analysis/Insights
The global cysticercosis treatment market is analysed and market size insights and trends are provided by drug, drug class, distribution channel and end-user as referenced above.
The major countries covered in the global cysticercosis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high diagnostic rate and presence of sophisticated medical facilities to maximize the treatment effectiveness for patient and increase focuses in the research and development activity.
Asia-Pacific dominates the market due to the growing cases of protozoan infections, developing healthcare facilities and presence of generic companies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cysticercosis Treatment Market Share Analysis
The global cysticercosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cysticercosis treatment market.
Key players operating in the global cysticercosis treatment market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Strides Pharma Science Limited (India)
SKU-